Drug-Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and Development

Chemical Research in Toxicology

Volumn 17, Issue 1, 2004, Pages 3-16

  Evans, David C ^a   Watt, Alan P ^b   Nicoll Griffith, Deborah A ^c   Baillie, Thomas A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Merck Sharp & Dohme Limited   (United Kingdom)

^c MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 7 [3 FLUORO 5 (3 HYDROXY 6,8 DIOXABICYCLO[3.2.1]OCT 3 YL)PHENOXYMETHYL] 4 (3 FURYL)QUINOLINE; 3 [6 [7 CYANO 5 (3 FURYL) 2 NAPHTHOXYMETHYL] 2 PYRIDYL] 3 HYDROXY 6,8 DIOXABICYCLO[3.2.1]OCTANE; AMIODARONE; AMODIAQUINE; AMOXICILLIN; BICALUTAMIDE; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; CIMETIDINE; CLOZAPINE; COTRIMOXAZOLE; DIAZEPAM; DICLOFENAC; DOXYCYCLINE; DRUG METABOLITE; ERYTHROMYCIN; ETHINYLESTRADIOL; HYDRALAZINE; INDOMETACIN; ISONIAZID; L 754394; LAMOTRIGINE; METHYLDOPA; ORAL CONTRACEPTIVE AGENT; PENICILLIN DERIVATIVE; PHENOBARBITAL; PHENYTOIN; PROCAINAMIDE; RADIOISOTOPE; SULFAMETHOXAZOLE; TICLOPIDINE; TRACER; UNINDEXED DRUG;

AGRANULOCYTOSIS; ALGORITHM; ANAPHYLAXIS; BLOOD DYSCRASIA; BONE MARROW TOXICITY; CARCINOGENICITY; CONFORMATIONAL TRANSITION; COVALENT BOND; DRUG ACTIVATION; DRUG DEVELOPMENT; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOMETRIUM CANCER; EPIDERMOLYSIS; EYE DISEASE; HEMOLYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; JAUNDICE; LIVER CELL; LIVER DISEASE; LIVER FAILURE; LIVER MICROSOME; LIVER TOXICITY; LUNG TOXICITY; MACROMOLECULE; MASS SPECTROMETRY; METABOLIC ACTIVATION; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN MODIFICATION; RASH; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SKIN MANIFESTATION; STANDARDIZATION; STEVENS JOHNSON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TECHNIQUE; TERATOGENICITY;

ANIMALS; BIOTRANSFORMATION; CLINICAL TRIALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG TOXICITY; HUMANS; PROTEIN BINDING; RESEARCH; RISK ASSESSMENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1642281756     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx034170b     Document Type: Review

References (107)

1. Fieser, L. F. (1938) Carcinogenic activity, structure, and chemical reactivity of polynuclear aromatic hydrocarbons. Am. J. Cancer 34, 37-124.
2. Miller, E. C., and Miller, J. A. (1947) The presence and significance of bound aminoazo dyes in the livers of rats fed p-dimethylaminoazobenzene. Cancer Res. 7, 468-480.
3. Miller, E. C., and Miller, J. A. (1952) In vivo combinations between carcinogens and tissue constituents and their possible role in carcinogenesis. Cancer Res. 12, 547-556.
4. Brodie, B. B., Reid, W. D., Cho, A. K., Sipes, G., Krishna, G., and Gillette, J. R. (1971) Possible mechanism of liver necrosis caused by aromatic organic compounds. Proc. Natl. Acad. Sci. U.S.A. 68, 160-164.
5. Gillette, J. R., Mitchell, J. R., and Brodie, B. B. (1974) Biochemical mechanisms of drug toxicity. Annu. Rev. Pharmacol. 14, 271-288.
6. Boyd, M. R., and Burka, L. T. (1978) In vivo studies on the relationship between target organ alkylation and the pulmonary toxicity of a chemically reactive metabolite of 4-ipomeanol. J. Pharmacol. Exp. Ther. 207, 687-697.
7. Boyd, M. R., Burka, L. T., and Wilson, B. J. (1975) Distribution, excretion, and binding of radioactivity in the rat after intraperitoneal administration of the lung-toxin furan, 4-ipomeanol. Toxicol. Appl. Pharmacol. 32, 147-157.
8. Boyd, M. R., Sasame, H. A., and Franklin, R. B. (1980) Comparison of ratios of covalent binding to total metabolism of the pulmonary toxin, 4-ipomeanol, in vitro in pulmonary and hepatic microsomes, and the effects of pretreatments with phenobarbital or 3-methylcholanthrene. Biochem. Biophys. Res. Commun. 93, 1167-1172.
9. Hinson, J. A., Pumford, N. R., and Roberts, D. W. (1995) Mechanisms of acetaminophen toxicity: immunochemical detection of drug-protein adducts. Drug Metab. Rev. 27, 73-92.
10. Satoh, H., Fukuda, Y., Anderson, D. K., Ferrans, V. J., Gillette. J. R., and Pohl, L. R. (1985) Immunological studies on the mechanism of halothane-induced hepatotoxicity: Immunohistochemical evidence of trifluoroacetylated hepatocytes. J. Pharmacol. Exp. Ther. 233, 857-862.
11. Uetrecht, J. P., Zahid, N., and Whitefield, D. (1994) Metabolism of vesnarinone by activated neutrophils: implications for vesnarinone-induced agranulocytosis. J. Pharmacol. Exp. Ther. 270, 865-872.
12. Snodgrass, W. R., Potter, W. Z., Timbrell, D. J., and Mitchell, J. R. (1975) Possible mechanisms of isoniazid-related hepatic injury. Clin. Res. 22, 323A.
13. Mitchell, J. R., Nelson, S. D., Snodgrass, W. R., and Timbrell, J. A. (1977) Metabolic activation of hydrazines to highly reactive hepatotoxic intermediates. In Biological Reactive Intermediates (Jollow, D., Kocsis, J., and Snyder, R., Eds.) pp 271-277, Plenum Press, New York.
14. Mitchell, J. R., Nelson, W. L., Potter, W. Z., Sasame, H. A., and Jollow, D. J. (1976) Metabolic activation of furosemide to a chemically reactive, hepatotoxic metabolite. J. Pharmacol. Exp. Ther. 199, 41-52.
15. Gardner, I., Leeder, J. S., Chin, T., Zahid, N., and Uetrecht, J. P. (1998) A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol. Pharmacol. 53, 999-1008.
16. Williams, D. P., Pirmohamed, M., Naisbitt, D. J., Maggs, J. L., and Park, B. K. (1997) Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J. Pharmacol. Exp. Ther. 283, 1375-1382.
17. Fisher, R., Brendel, K., and Hanzlik, R. P. (1993) Correlation of metabolism, covalent binding and toxicity for a series of bromobenzene derivatives using rat liver slices in vitro. Chem.-Biol. Interact. 88, 191-208.
18. Koen, Y. M., and Hanzlik, R. P. (2002) Identification of seven proteins in the endoplasmic reticulum as targets for reactive metabolites of bromobenzene. Chem. Res. Toxicol. 15, 699-706.
19. Weller, P. E., Narasimhan, N., Buben, J. A., and Hanzlik, R. P. (1988) In vitro metabolism and covalent binding among orthosubstituted bromobenzenes of varying hepatotoxicity. Drug Metab. Dispos. 16, 232-237.
20. Tirmenstein, M. A., and Nelson, S. D. (1989) Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3′-hydroxyacetanilide, in mouse liver. J. Biol. Chem. 264, 9814-9819.
21. Pumford, N. R., and Halmes, N. C. (1997) Protein targets of xenobiotic reactive intermediates. Annu. Rev. Pharmacol. Toxicol. 37, 91-117.
22. Qiu, Y., Benet, L. Z., and Burlingame, A. L. (1998) Identification of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry. J. Biol. Chem. 273, 17940-17953.
23. Cohen, S. D., Pumford, N. R., Khairallah, E. A., Boekelheide, K., Pohl, L. R., Amouzadeh, H. R., and Hinson, J. A. (1997) Selective protein covalent binding and target organ toxicity. Toxicol. Appl. Pharmacol. 143, 1-12.
24. Naisbitt, D. J., Gordon, S. F., Pirmohamed, M., and Park, B. K. (2000) Immunological principles of adverse drug reactions-The initiation and propagation of immune responses elicited by drug treatement. Drug Saf. 23, 483-507.
25. Baillie, T. A., and Davis, M. R. (1993) Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass. Spectrom. 22, 319-325.
26. Gorrod, J. W., and Aislaitner, G. (1994) The metabolism of alicyclic amines to reactive iminium ion intermediates. Eur. J. Drug Metab. Pharmacokinet. 19, 209-217.
27. 14C-sodium cyanide during microsomal oxidation. Adv. Exp. Med. Biol. 283, 657-664.
28. Uetrecht, J. (1999) New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem. Res. Toxicol. 12, 387-395.
29. Back, D. J., Breckenridge, A. M., MacIver, M., Orme, M., Purba, H. S., Rowe, P. H., and Taylor, I. (1982) The gut wall metabolism of ethinylestradiol and its contribution to the presystemic metabolism of ethyinylestradiol in humans. Br. J. Clin. Pharmacol. 13, 325-330.
30. Rogers, S. M., Back, D. J., and Orme, M. L. (1987) Intestinal metabolism of ethinyloestradiol and paracetamol in vitro: studies using Ussing chambers. Br. J. Clin. Pharmacol. 23, 727-734.
31. Boobis, A. R., Burley, D., Davies, D. M., Davies, D. S., Harrison, P. I., Orme, M. L'E., Park, B. K., and Goldberg, L. I. (1991) In Therapeutic Drugs (Dollery, C., Ed.) Churchill, Livingston.
32. Tang, W., Stearns, R. A., Bandiera, S. M., Zhang, Y., Raab, C., Braun, M. P., Dean, D. C., Pang, J., Leung, K. H., Doss, G. A., Strauss, J. R., Kwei, G. Y., Rushmore, T. H., Chiu, S. L., and Baillie, T. A. (1999) Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. Drug Metab. Dispos. 27, 365-372.
33. Shen, S., Marchick, M. R., Davis, M. R., Doss, G. A., and Pohl, L. R. (1999) Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem. Res. Toxicol. 12, 214-222.
34. Poon, G. K., Chen, Q., Teffera, Y., Ngui, J. S., Griffin, P. R., Braun, M. P., Doss, G. A., Freeden, C., Stearns, R. A., Evans, D. C., Baillie, T. A., and Tang, W. (2001) Bioactivation of diclofenac via benzoquinoneimine intermediates-identification of urinary mercapturic acid derivatives in rats and humans. Drug Metab. Dispos. 29, 1608-1613.
35. Bougie, D., Johnson, S. T., Weitekamp, L. A., and Aster, R. H. (1997) Sensitivity to a metabolite of diclofenac as a cause of acute immune hemolytic anemia. Blood 90, 407-413.
36. Weaver, G. A., Pavlinac, D., and Davis, J. (1977) Hepatic sensitivity to imipramine. Am. J. Dig. Dis. 22, 551-553.
37. Short, M. H., Burns, J. M., and Harris, M. E. (1968) Cholestatic jaundice during imipramine therapy. J. Am. Med. Assoc. 206, 1791-1792.
38. Koyama, E., Chiba, K., Tani, M., and Ishizaki, T. (1997) Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J. Pharmacol. Exp. Ther. 281, 1199-1210.
39. Masubuchi, Y., Igarashi, S., Suzuki, T., Horie, T., and Narimatsu, S. (1996) Imipramine-induced inactivation of a cytochrome P450 2D enzyme in rat liver microsomes in relation to covalent binding of its reactive intermediates. J. Pharmacol. Exp. Ther. 279, 724-731.
40. Rinaldi, R., Eliasson, E., Swedmark, S., and Morgenstern, R. (2002) Reactive intermediates and the dynamics of glutathione transferases. Drug Metab. Dispos. 30, 1053-1058.
41. Kalgutkar, A., Dalvie, D. K., O'Donnell, J. P., Taylor, T. J., and Sahakian D. C. (2002) On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics. Curr. Drug Metab. 3, 379-424.
42. Chauret, N., Nicoll-Griffith, D., Friesen, R., Li, C., Trimble, L., Dube, D., Fortin, R., Girard, Y., and Yergey, J. (1995) Microsomal metabolism of the 5-lipoxygenase inhibitors L-746530 and L-739010 to reactive intermediates that covalently bind to protein: the role of the 6,8-dioxobicyclo[3.2.1]octanyl moiety. Drug Metab. Dispos. 23, 1325-1334.
43. Zhang, K. E., Naue, J. A., Arison, B., and Vyas, K. P. (1996) Microsomal metabolism of the 5-lipoxygenase inhibitor L-739010: Evidence for furan bioactivation. Chem. Res. Toxicol. 9, 547-554.
44. Doss, G. A., Miller, R. R., Zhang, Z., Teffera, Y., Evans, D. C., Baillie, T. A., Stearns, R. S., et al. Unpublished observations.
45. Singh, R., Silva-Elipe, M. V., Pearson, P. G., Arison, B. H., Wong, B. K., White, R., Yu, X., Burgey, C. S., Lin, J. H., and Baillie, T. A. (2003) Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins. Chem. Res. Toxicol. 16, 198-207.
46. Samuel, K., Yin, W., Stearns, R. A., Tang, Y. S., Chaudhary, A. G., Jewell, J. P., Lanza, T., Lin, L. S., Hagmann, W. K., Evans, D. C., and Kumar, S. (2003) Rapidly addressing the metabolic activation potential of new leads in drug discovery: A case study using ion trap mass spectrometry and tritium labeling techniques. J. Mass Spectrom. 38, 211-221.
47. Park, B. K., Kitteringham, N. R., and O'Neill, P. M. (2001) Metabolism of fluorine-containing drugs. Annu. Rev. Pharmacol. Toxicol. 41, 443-470.
48. Park, B. K., and Kitteringham, N. R. (1994) Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications. Drug Metab. Rev. 26, 605-643.
49. Badghisi, H., and Liebler, D. C. (2002) Sequence mapping of epoxide adducts in human hemoglobin with LC-Tandem MS and the Salsa algorithm. Chem. Res. Toxicol. 15, 799-805.
50. Amiodarone. Bicalutamide. Lamotrigine. Physicians Desk Reference (PDR) (2003) 57th ed., pp 656, 1559, 3384, Thomson PDR, Montvale.
51. Jewell, H., Maggs, J. L., Harrison, A. C., O'Neill, P. M., Ruscoe, J. E., and Park, B. K. (1995) Role of hepatic metabolism in the bioactivation and detoxication of amodiaquine. Xenobiotica 25, 199-217.
52. Bigby, M., Jick, S., Jick, H., and Arndt, K. (1986) Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. J. Am. Med. Assoc. 256, 3358-3363.
53. Askmark, H., and Wiholm, B. E. (1990) Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol. Scand. 81, 131-140.
54. Alvir, J. M., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., and Schaaf, J. A. (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. New Engl. J. Med. 329, 162-167.
55. Alarcon-Segovia, D. Drug-induced lupus syndromes. (1969) Mayo Clin. Proc. 44, 664-681.
56. Park, B. K., Pirmohamed, M., and Kitteringham, N. R. (1998) Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem. Res. Toxicol. 11, 969-988.
57. Weiss, M. E., and Adkinson, N. F. (1988) Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin. Allergy 18, 515-540.
58. Shear, N. H., and Spielberg, S. P. (1988) Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J. Clin. Invest. 82, 1826-1832.
59. Lee, S. L., and Chase, P. H. (1975) Drug-induced systemic lupus erythematosus: a critical review. Semin. Arthritis Rheum. 5, 83-103.
60. Mandell, G. L., and Sande, M. A (1985) Anti-microbial agents: Sulfonamides, trimethoprim-sulphamethoxazole and agents for urinary tract infections. In The Pharmacological Basis of Therapeutics (Gilman A. G., Goodman, L. S., Rall, T. W., and Marud, R., Eds.) pp 1095-1114, McGraw-Hill, New York.
61. Ono, K., Kurohara, K., Yoshihara, M., Shimamoto, Y., and Yamaguchi, M. (1991) Agranulocytosis caused by ticlopidine and its mechanism. Am. J. Hematol. 37, 239-242.
62. Harrison, A. C., Kitteringham, N. R., Clarke, J. B., and Park, B. K. (1992) The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem. Pharmacol. 43, 1421-1430.
63. Maggs, J. L., Grabowski, P. S., and Park, B. K. (1983) Drug protein conjugates-III. Inhibition of the irreversible binding of ethyinylestradiol to rat liver microsomal protein by mixed-function oxidase inhibitors, ascorbic acid and thiol. J. Steroid Biochem. 19, 1273-1278.
64. Maggs, J. L., Grabowski, P. S., Rose, M. E., and Park, B. K. (1982) The biotransformation of 17α-ethynyl[3H]estradiol in the rat: irreversible binding and biliary metabolites. Xenobiotica 12, 657-668.
65. Maggs, J. L., Grabowski, P. S., and Park, B. K. (1983) Drug-protein conjugates-II. An investigation of the irreversible binding and metabolism of 17α-ethinyl estradiol in vivo. Biochem. Phar. macol. 32, 301-308.
66. Nelson, S. D., Mitchell, J. R., Sodgrass, W. R., and Timbrell, J. A. (1978) Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine. J. Pharmacol. Exp. Ther. 206, 574-585.
67. Nelson, S. D., Mitchell, J. R., Timbrell, J. A., Sodgrass, W. R., and Corcoran, G. B. (1976) Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science 193, 901-903.
68. Hinson, J. A., and Mays, J. B. (1986) Covalent binding of the phenacetin metabolite p-nitrosophenetole to protein. J. Pharma. col. Exp. Ther. 238, 106-112.
69. Buhler, D. R., Unlu, F., Thakker, D. R., Slaga, T. J., Conney, A. H., Wood, A. W., Chang, R. L., Levin, W., Jerina, D. M. (1983) Effect of a 6-fluoro substituent on the metabolism and biological activity of benzo[a]pyrene. Cancer Res. 43, 1541-1549.
70. Monks, T. J., Lau, S. S., Highet, R. J., and Gillette, J. R. (1985) Glutathione conjugates of 2-bromohydroquinone are nephrotoxic. Drug Metab. Dispos. 13, 553-559.
71. Lillibridge, J. H., Amore, B. M., Slattery, J. T., Kalhorn, T. F., Nelson, S. D., Finnell, R. H., and Bennett, G. D. (1996) Protein-reactive metabolites of carbamazepine in mouse liver microsomes. Drug Metab. Dispos. 24, 509-514.
72. Munns, A. J., De Voss, J. J., Hooper, W. D., Dickinson, R. G., and Gillam, E. M. J. (1997) Bioactivation of phenytoin by human cytochrome P450: Characterization of the mechanism and targets of covalent adduct formation. Chem. Res. Toxicol. 10, 1049-1058.
73. Cuttle, L., Munns, A. J., Hogg, N. A., Scott, J. R., Hooper, W. D., Dickinson, R. G., and Gillam, E. M. J. (2000) Phenytoin metabolism by human cytochrome P450: Involvement of P4503A and 2C forms in secondary metabolism and drug-protein adduct formation. Drug Metab. Dispos. 28, 945-950.
74. Buckpitt, A. R., Castagnoli, N., Nelson, S. D., Jones, A. D., and Bahnson, L. S. (1987) Stereoselectivity of naphthalene epoxidation by mouse, rat, and hamster pulmonary, hepatic, and renal microsomal enzymes. Drug Metab. Dispos. 15, 491-498.
75. Wilson, A. S., Davis, C. D., Williams, D. P., Buckpitt, A. R., Pirmohamed, M., and Park, B. K. (1997) Characterization of the toxic metabolite(s) of naphthalene. Toxicology 114, 233-242.
76. Iverson, S. L., Shen, L., Anlar, N., and Bolton, J. L. (1996) Bioactivation of estrone and its catechol metabolites to quinoidglutathione conjugates in rat liver microsomes. Chem. Res. Toxicol. 9, 492-499.
77. Shen, L., Qiu, S., Chen, Y., Zhang, F., van Breemen, R. B., Nikolic, D., and Bolton, J. L. (1998) Alkylation of 2′-deoxynucleosides and DNA by the premarin metabolite 4-hydroxyequilenin semiquinone radical. Chem. Res. Toxicol. 11, 94-101.
78. Fan, P. W., Zhang, F., and Bolton, J. L. (2000) 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides. Chem. Res. Toxicol. 13, 45-52.
79. Zhang, F., Fan, P. W., Liu, X., Shen, L., van Breemen, R. B., and Bolton, J. L. (2000) Synthesis and reactivity of a potential carcinogenic metabolite of tamoxifen: 3,4-dihydroxytamoxifen-o-quinone. Chem. Res. Toxicol. 13, 53-62.
80. Dehal, S. S., and Kupfer, D. (1999) Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (Droloxifene) yielding tamoxifen catechol: Involvement of catechols in covalent binding to hepatic proteins. Drug Metab. Dispos. 27, 681-688.
81. Chen, Q., Ngui, J. S., Doss, G. A., Wang, R. W., Cai, X., DiNinno, F. P., Blizzard, T. A., Hammond, M. L., Stearns, R. A., Evans, D. C., Baillie, T. A., and Tang, W. (2002) Cytochrome P450 3A4-mediated bioactivation of Raloxifene: Irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol. 15, 907-914.
82. 14C]practolol metabolite(s) to mammalian liver microsomes. J. Pharmacol. Exp. Ther. 219, 207-212.
83. Khojasteh-Bakht, S. C., Koenigs, L. L., Peter, R. M., Trager, W. F., and Nelson, S. D. (1998) (R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6. Drug Metab. Dispos. 26, 701-704.
84. Sahali-Sahly, Y., Balani, S. K., Lin, J. H., and Baillie, T. A. (1996) In vitro studies on the metabolic activation of the furanopyridine L-754394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4. Chem. Res. Toxicol. 9, 1007-1012.
85. Bartolone, J. B., Beierschmitt, W. P., Birge, R. B., Hart, S. G. E., Wyand, S., Cohen, S. D., and Khairallah, E. A. (1989) Selective acetaminophen metabolite binding to hepatic and extrahepatic proteins: An in vivo and in vitro analysis. Toxicol. Appl. Pharmacol. 99, 240-249.
86. Meyers, L. L., Beierschmitt, W. P., Khairallah, E. A., and Cohen, S. D. (1988) Acetaminophen-induced inhibition of hepatic mitochondrial respiration in mice. Toxicol. Appl. Pharmacol. 93, 378-387.
87. Kretz-Rommel, A., and Boelsterli, U. A. (1994) Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins. Retention of the glucuronic acid moiety in the adduct. Drug Metab. Dispos. 22, 956-961.
88. Kretz-Rommel, A., and Boelsterli, U. A. (1994) Selective protein adducts to membrane proteins in cultured rat hepatocytes exposed to diclofenac: radiochemical and immunochemical analysis. Mol. Pharmacol. 45, 237-244.
89. Pumford, N. R., Myers, T. G., Davila, J. C., Highet, R. J., and Pohl, L. R. (1993) Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac. Chem. Res. Toxicol. 6, 147-150.
90. Kretz-Rommel, A., and Boelsterli, U. A. (1993) Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. Toxicol. Appl. Pharmacol. 120, 155-161.
91. Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., and Baillie, T. A. (2001) Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 14, 62-70.
92. Tettey, J. N., Maggs, J. L., Rapeport, W. G., Pirmohamed, M., and Park, B. K. (2001) Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem. Res. Toxicol. 14, 965-974.
93. Yost, G. S. (1989) Mechanisms of 3-methylindole pneumotoxicity. Chem. Res. Toxicol. 2, 273-279.
94. Ruangyuttikarn, W. A., Martin, L., and Yost, G. S. (1991) Metabolism of 3-methylindole in human tissues. Drug Metab. Dispos. 19, 977-984.
95. Ruangyuttikarn, W., Skiles, G. L., and Yost, G. S. (1992) Identification of a cysteinyl adduct of oxidized 3-methylindole from goat lung and human liver microsomal proteins. Chem. Res. Toxicol. 5, 713-719.
96. Tang, W., and Abbott, F. S. (1996) Bioactivation of a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, via glucuronidation. LC/MS/MS characterization of the GSH-glucuronide diconjugates. Chem. Res. Toxicol. 9, 517-526.
97. Sadeque, A. J. M., Fisher, M. B., Korzekwa, K. R., Gonzalez, F. J., and Rettie, A. E. (1997) Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J. Pharmacol. Exp. Ther. 283, 698-703.
98. Porubek, D. J., Grillo, M. P., and Baillie, T. A. (1989) The covalent binding to protein of valproic acid and its hepatotoxic metabolite, 2-n-propyl-4-pentenoic acid, in rats and in isolated rat hepatocytes. Drug Metab. Dispos. 17, 123-130.
99. Baillie, T. A. (1988) Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid. Chem. Res. Toxicol. 1, 195-199.
100. Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., and Bor, D. H. (2002) Timing of new black box warnings and withdrawals for prescription medications. J. Am. Med. Assoc. 287, 2215-2220.
101. Mouelhi, M., Ruelius, H. W., Fenselau, C., and Dulik, D. M. (1987) Species-dependent enantioselective glucuronidation of three 2-arylpropionic acids. Naproxen, ibuprofen, and benoxaprofen. Drug Metab. Dispos. 15, 767-772.
102. Castillo, M., and Smith, P. C. (1995) Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin. Drug Metab. Dispos. 23, 566-572.
103. Smith, P. C., Benet, L. Z., and McDonagh, A. F. (1990) Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism. Drug Metab. Dispos. 18, 639-644.
104. Smith, P. C., McDonagh, A. F., and Benet, L. Z. (1986) Irreversible binding of zomepirac to plasma protein in vitro and in vivo. J. Clin. Invest. 77, 934-939.
105. Smith, P. C., and Benet, L. Z. (1986) Characterization of the isomeric esters of zomepirac glucuronide by proton NMR. Drug Metab. Dispos. 14, 503-505.
106. Lecoeur, S., Bonierbale, E., Challine, D., Gautier, J.-C., Valadon, P., Dansette, P. M., Catinot, R., Ballet, F, Mansuy, D., and Beaune, P. H. (1994) Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. Chem. Res. Toxicol. 7, 434-442.
107. Koenigs, L. L., Peter, R. M., Hunter, A. P., Haining, R. L., Rettie, A. E., Friedberg, T., Pritchard, M. P., Shou, M., Rushmore, T. H., and Trager, W. F. (1999) Electrospray ionization mass spectrometric analysis of intact cytochrome P450: Identification of tienilic acid adducts to P450 2C9. Biochemistry 38, 2312-2319.